Preview

Head and Neck Tumors (HNT)

Advanced search

Aggressive forms of pituitary adenomas (literature review and clinical observation)

https://doi.org/10.17650/2222-1468-2017-7-4-846

Abstract

Introduction. Pituitary adenomas comprise 10–15 % of all intracranial tumors. Despite being benign tumors, 25–55 % of them exhibit invasive growth spreading into surrounding structures (sphenoid sinus, cavernous sinus, etc.). In literature, there isn’t a generally accepted definition of aggressive pituitary adenomas. As a result, there aren’t any studies reporting on the therapy of choice for this disease, except for several reports on using temozolomide as a “salvage” therapy in patients who didn’t respond to standard treatment methods.
We present a clinical observation of a patient with “refractory” pituitary adenoma who successfully underwent 4 surgical interventions and 2 courses of high-dose stereotactic radiotherapy.
Results. Application of stereotactic radiotherapy at high (59.4 Gy) dose, which is usually used for treatment of patients with malignant tumors, allowed to achieve long recurrence-free period of 5.5 years (65 months). Observation has shown that repeated courses of stereotactic irradiation can be sufficiently effective and safe in patients with large and gigantic tumors including “refractory” pituitary adenoma.
Conclusion. Further studies are necessary for specification of parameters of “refractory” adenomas and their detection at the early stages of diagnosis. Confirmed diagnosis requires more aggressive surgical, radiological, and drug treatment.

About the Authors

P. L. Kalinin
N. N. Burdenko National Medical Research Center for Neurosurgery, Ministry of Health of Russia;
Russian Federation

16 4th Tverskaya-Yamskaya St., Moscow 125047, Russia



Yu. Yu. Trunin
N. N. Burdenko National Medical Research Center for Neurosurgery, Ministry of Health of Russia;
Russian Federation
16 4th Tverskaya-Yamskaya St., Moscow 125047, Russia


D. V. Fomichev
N. N. Burdenko National Medical Research Center for Neurosurgery, Ministry of Health of Russia;
Russian Federation
16 4th Tverskaya-Yamskaya St., Moscow 125047, Russia


I. V. Chernov
N. N. Burdenko National Medical Research Center for Neurosurgery, Ministry of Health of Russia;
Russian Federation
16 4th Tverskaya-Yamskaya St., Moscow 125047, Russia


M. V. Ryzhova
N. N. Burdenko National Medical Research Center for Neurosurgery, Ministry of Health of Russia;
Russian Federation
16 4th Tverskaya-Yamskaya St., Moscow 125047, Russia


References

1. Asa S. L., Ezzat S. The cytogenesis and pathogenesis of pituitary adenomas [review]. Endocr Rev 1998;19(6):798–827. DOI:10.1210/edrv. 19.6.0350.

2. Lloyd R. V., Kovacs K., Young W. F. Jr et al. Pituitary tumors: introduction. In: World Health Organization classification of tumours. Pathology and genetics of tumours of endocrine organs. Eds: R. A. DeLellis, R. V. Lloyd, P. U. Heitz et al. Lyon (France): IARC Press; 2004. P. 9–13.

3. Zada G., Woodmansee W. W., Ramkissoon S. et al. Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J Neurosurg 2011;114:336–44. DOI: 10.3171/ 2010.8.JNS10290. PMID: 20868211.

4. Zaidi H. A., Cote D. J., Dunn I. F., Laws E. R.Jr. Predictors of aggressive clinical phenotype among immunohistochemically confirmed atypical adenomas. J Clin Neurosci 2016;34:246–51. DOI: 10.1016/j.jocn.2016.09.014. PMID: 27765563.

5. Chiloiro S., Doglietto F., Trapasso B. et al. Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis. Neuroendocrinology 2015;101(2): 143–50. DOI: 10.1159/000375448.

6. Mete O., Lopes M. B. Overview of the 2017 WHO Classification of Pituitary Tumors. Endocr Pathol 2017 Aug 1. DOI: 10.1007/ s12022-017-9498-z. PMID: 28766057.

7. Lopes M. B. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol 2017 Aug 18. DOI: 10.1007/ s00401-017-1769-8. PMID: 28821944.

8. Alahmadi H., Lee D., Wilson J. R. et al. Clinical features of silent corticotroph adenomas. Acta Neurochir (Wien) 2012;154(8):1493–8. DOI: 10.1007/ s00701-012-1378-1. PMID: 22619024.

9. Xu Z., Ellis S., Lee C. C. et al. Silent corticotroph adenomas after stereotactic radiosurgery: a case-control study. Int J Radiat Oncol Biol Phys 2014;90(4):903–10. DOI: 10.1016/j.ijrobp.2014.07.013. PMID: 25216855.

10. Heaney A. Management of aggressive pituitary adenomas and pituitary carcinomas. J Neurooncol 2014;117:459–68. DOI: 10.1007/s11060-014-1413-6. PMID: 24584748.

11. Кадашев Б. А., Астафьева Л. И., Шишкина Л. В. и др. Cовременный взгляд на проблему карциномы гипофиза. Вестник РОНЦ им. Н. Н. Блохина РАМН 2010;21(4):52–8. [Kadashev B. A., Astafieva L. I., Shishkina L. V. et al. A contemporary view of pituitary carcinoma. Vestnik RONC im. Blokhina = Journal of N. N. Blokhin Russian Cancer Research Center RAMS 2010;21(4):52–8. (In Russ.)].

12. Астафьева Л. И., Коршунов А. Г., Кадашев Б. А. и др. Пролактинсекретирующая карцинома гипофиза. Вопросы нейрохирургии им. Н. Н. Бурденко 2004;1:37–40. [Astafieva L. I., Korshunov A. G., Kadashev B. A. et al. Prolactin-secreting pituitary carcinoma. Voprosy neyrokhirurgii imeni N. N. Burdenko = Burdenko’s Journal of Neurosurgery 2004;1:37–40. (In Russ.)].

13. Kaltsas G. A., Nomikos P., Kontogeorgos G. et al. Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 2005;90:3089– 99. DOI:10.1210/jc.2004–2231. PMID: 15741248.

14. Scheithauer B. W., Kovacs K. T., Laws E. R. Jr, Randall R. V. Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg 1986;65:733–44. DOI: 10.3171/jns.1986.65.6.0733. PMID: 3095506.

15. Thapar K., Kovacs K., Scheithauer B. W. et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 1996;38(1):99–106. DOI: 10.1097/00006123-199601000-00024. PMID: 874757.

16. Meij B. P., Lopes M. B., Ellegala D. B. et al. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J Neurosurg 2002;96(2):195– 208. DOI: 10.3171/jns.2002.96.2.0195. PMID: 11838791.

17. Калинин П. Л., Фомичев Д. В., Кутин М. А. и др. Эндоскопическая эндоназальная хирургия аденом гипофиза (опыт 1700 операций). Вопросы нейpохиpуpгии им. Н. Н. Буpденко 2012;3:26–33. [Kalinin P. L., Fomichev D. V., Kutin M. A. et al. Endoscopic endonasal surgery of pituitary adenomas (experience of 1700 operations). Voprosy neyrokhirurgii imeni N. N. Burdenko = Burdenko’s Journal of Neurosurgery 2012;3:26–33. (In Russ.)].

18. Sav A., Rotondo F., Syro L. V. et al. Invasive, atypical and aggressive pituitary adenomas and carcinomas. Endocrinol Metab Clin North Am 2015;44(1):99–104. DOI:10.1016/j.ecl.2014.10.008. PMID: 25732646.

19. Liu J. K., Patel J., Eloy J. A. The role of temozolomide in the treatment of aggressive pituitary tumors. J Clin Neurosci 2015;22(6):923–9. DOI: 10.1016/ j.jocn.2014.12.007. PMID: 25772801.

20. Priola S. M., Esposito F., Cannavò S. et al. Aggressive pituitary adenomas: the dark side of the moon. World Neurosurg 2017;97:140–55. DOI: 10.1016/ j.wneu.2016.09.092. PMID: 27713064.

21. Hagen C., Schroeder H. D., Hansen S. et al. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrin 2009;161(4): 631–7. DOI: 10.1530/EJE-09-0389. PMID: 19654234.

22. McCormack A.I., McDonald K.L., Gill A. J. et al. Low O6-methylguanineDNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf) 2009;71(2):226–33. DOI: 10.1111/j. 1365-2265.2008.03487.x. PMID: 19067722.

23. Dillard T. H., Gultekin S. H., Delashaw J. B. Jr. et al. Temozolomide for corticotroph pituitary adenomas refractory to standard therapy. Pituitary 2011;14(1):80–91. DOI: 10.1007/s11102-010-0264-1. PMID: 20972839.

24. Jaffrain-Rea M. L., Di Stefano D., Minniti G. et al. A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus nonsecreting adenomas. Endocr Relat Cancer 2002;9:103–13. DOI: 10.1677/ erc.0.0090103. PMID: 12121834.

25. Saeger W., Lüdecke D. K., Buchfelder M. et al. Pathohistological classification of pituitary tumors: 10 years of experience with the German pituitary tumor registry. Eur J Endocrinol 2007;156:203–16. DOI: 10.1530/eje.1.02326. PMID: 17287410.

26. Popescu M. N., Ionescu E., Iovanescu L. C. et al. Clinical aggression of prolactinomas: correlations with invasion and recurrence. Rom J Morphol Embryol 2013;54(4): 1075–80. PMID: 24399004.

27. Dai C., Feng M., Liu X. et al. Refractory pituitary adenoma: a novel classification for pituitary tumors. Oncotarget 2016;7(50): 83657–68. DOI: 10.18632/oncotarget.13274. PMID: 27845901.


Review

For citations:


Kalinin P.L., Trunin Yu.Yu., Fomichev D.V., Chernov I.V., Ryzhova M.V. Aggressive forms of pituitary adenomas (literature review and clinical observation). Head and Neck Tumors (HNT). 2017;7(4):74-80. (In Russ.) https://doi.org/10.17650/2222-1468-2017-7-4-846

Views: 890


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2222-1468 (Print)
ISSN 2411-4634 (Online)